Vertex Financial Statements From 2010 to 2024

VRTX Stock  USD 400.76  0.00  0.00%   
Vertex Pharmaceuticals financial statements provide useful quarterly and yearly information to potential Vertex Pharmaceuticals investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Vertex Pharmaceuticals financial statements helps investors assess Vertex Pharmaceuticals' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Vertex Pharmaceuticals' valuation are summarized below:
Gross Profit
5.3 B
Profit Margin
0.3668
Market Capitalization
104.7 B
Enterprise Value Revenue
9.3342
Revenue
9.9 B
We have found one hundred twenty available fundamental trend indicators for Vertex Pharmaceuticals, which can be analyzed and compared to other ratios and to its competition. All investors should make sure to double-check all of Vertex Pharmaceuticals current market performance against the performance between 2010 and 2024 to make sure the company can sustain itself down the road. Market Cap is likely to drop to about 8.4 B in 2024. Enterprise Value is likely to drop to about 8.3 B in 2024

Vertex Pharmaceuticals Total Revenue

10.33 Billion

Check Vertex Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Vertex main balance sheet or income statement drivers, such as Total Revenue of 10.3 B, Gross Profit of 9 B or Other Operating Expenses of 6.4 B, as well as many exotic indicators such as Price To Sales Ratio of 10.12, Dividend Yield of 0.002 or PTB Ratio of 7.46. Vertex financial statements analysis is a perfect complement when working with Vertex Pharmaceuticals Valuation or Volatility modules.
  
This module can also supplement Vertex Pharmaceuticals' financial leverage analysis and stock options assessment as well as various Vertex Pharmaceuticals Technical models . Check out the analysis of Vertex Pharmaceuticals Correlation against competitors.
For more information on how to buy Vertex Stock please use our How to Invest in Vertex Pharmaceuticals guide.

Vertex Pharmaceuticals Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets23.9 B22.7 B8.2 B
Slightly volatile
Short and Long Term Debt Total848.8 M808.4 M604.4 M
Slightly volatile
Total Current Liabilities3.7 B3.5 B1.2 B
Slightly volatile
Total Stockholder Equity18.5 B17.6 B5.9 B
Slightly volatile
Property Plant And Equipment Net1.5 B1.5 B791.1 M
Slightly volatile
Cash10.9 B10.4 B3.7 B
Slightly volatile
Non Current Assets TotalB8.6 BB
Slightly volatile
Non Currrent Assets Other836.5 M796.7 M368.3 M
Slightly volatile
Cash And Short Term Investments11.8 B11.2 B4.3 B
Slightly volatile
Common Stock Shares Outstanding153.1 M260.5 M223.3 M
Slightly volatile
Liabilities And Stockholders Equity23.9 B22.7 B8.2 B
Slightly volatile
Non Current Liabilities Total1.7 B1.6 B1.3 B
Slightly volatile
Other Current Assets651.5 M620.5 M220.8 M
Pretty Stable
Other Stockholder Equity7.8 B7.4 B6.2 B
Slightly volatile
Total Liabilities5.4 B5.1 B2.3 B
Slightly volatile
Total Current Assets14.9 B14.1 B5.2 B
Slightly volatile
Short Term Debt51 M83.7 M69.4 M
Very volatile
Accounts Payable383.1 M364.9 M140.6 M
Slightly volatile
Property Plant And Equipment Gross2.8 B2.6 B1.1 B
Slightly volatile
Net Receivables1.6 B1.6 B590.9 M
Slightly volatile
Common Stock Total Equity1.9 MM2.3 M
Slightly volatile
Common StockMM2.3 M
Slightly volatile
Other Assets1.7 B1.6 B618.2 M
Slightly volatile
Long Term Debt446.2 M646.2 M554.3 M
Pretty Stable
Short Term Investments579.6 M849.2 M558.1 M
Pretty Stable
Property Plant Equipment1.8 B1.7 B851.9 M
Slightly volatile
Other Liabilities828.1 M788.7 M365.2 M
Slightly volatile
Current Deferred Revenue118.8 M170.3 M135.4 M
Slightly volatile
Inventory775.7 M738.8 M222.7 M
Slightly volatile
Good Will1.3 B1.3 B548 M
Slightly volatile
Intangible Assets424.7 M839.9 M379.8 M
Pretty Stable
Long Term Debt Total632.6 M619.9 M577.1 M
Pretty Stable
Capital Surpluse6.9 B8.5 B6.4 B
Slightly volatile
Deferred Long Term Liabilities6.9 M7.3 M98.3 M
Slightly volatile
Non Current Liabilities Other186.5 M196.3 M358.1 M
Slightly volatile
Capital Lease Obligations848.8 M808.4 M270.5 M
Slightly volatile
Short and Long Term Debt732.3 M697.4 M367.4 M
Slightly volatile
Long Term Investments2.6 B2.5 B383.5 M
Slightly volatile
Net Invested Capital9.9 B17.6 B5.8 B
Slightly volatile
Net Working Capital6.6 B10.6 B4.1 B
Slightly volatile
Capital Stock2.8 MM2.6 M
Slightly volatile

Vertex Pharmaceuticals Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Total Revenue10.3 B9.8 BB
Slightly volatile
Gross ProfitB8.6 B3.5 B
Slightly volatile
Other Operating Expenses6.4 B6.1 B2.7 B
Slightly volatile
Total Operating Expenses5.1 B4.8 B2.2 B
Slightly volatile
Depreciation And Amortization190.4 M181.3 M96.8 M
Slightly volatile
Research Development3.9 B3.7 B1.7 B
Slightly volatile
Selling General Administrative1.2 B1.1 B590.8 M
Slightly volatile
Extraordinary Items1.9 B1.8 B1.5 B
Slightly volatile
Non Recurring102.7 M104 M122.4 M
Very volatile
Interest Income645.4 M614.7 M144.9 M
Slightly volatile
Reconciled Depreciation126.6 M181.3 M90.8 M
Slightly volatile

Vertex Pharmaceuticals Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow11 B10.5 B3.1 B
Slightly volatile
Depreciation190.4 M181.3 M87.1 M
Slightly volatile
Capital Expenditures271.3 M258.4 M135.4 M
Slightly volatile
End Period Cash Flow10.9 B10.4 B3.7 B
Slightly volatile
Stock Based Compensation610.3 M581.2 M303.1 M
Slightly volatile
Change To Netincome437.4 M512.4 M407.9 M
Slightly volatile
Issuance Of Capital Stock347.9 M394.7 M314.6 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio10.1210.657115.1092
Slightly volatile
Dividend Yield0.0020.00210.0037
Slightly volatile
PTB Ratio7.465.964311.7428
Slightly volatile
Days Sales Outstanding38.4557.997946.8195
Slightly volatile
Book Value Per Share71.6368.220423.0556
Slightly volatile
Invested Capital0.04370.0460.3769
Slightly volatile
Stock Based Compensation To Revenue0.05610.05910.1037
Pretty Stable
PB Ratio7.465.964311.7428
Slightly volatile
EV To Sales9.29.685114.6591
Slightly volatile
Inventory Turnover1.621.70843.4595
Slightly volatile
Days Of Inventory On Hand111214151
Very volatile
Research And Ddevelopement To Revenue0.360.3750.657
Slightly volatile
Cash Per Share45.7243.544817.0536
Slightly volatile
Intangibles To Total Assets0.150.08480.1259
Slightly volatile
Current Ratio3.793.987218.3538
Very volatile
Tangible Book Value Per Share63.7860.739219.6055
Slightly volatile
Receivables Turnover9.086.29338.2198
Slightly volatile
Graham Number15414753.0273
Slightly volatile
Shareholders Equity Per Share71.6368.220423.0556
Slightly volatile
Debt To Equity0.04370.0460.3769
Slightly volatile
Revenue Per Share40.0938.180115.8679
Slightly volatile
Interest Debt Per Share1.813.30812.8169
Very volatile
Debt To Assets0.03380.03560.1816
Slightly volatile
Operating Cycle285272203
Pretty Stable
Price Book Value Ratio7.465.964311.7428
Slightly volatile
Company Equity Multiplier1.81.29291.8142
Slightly volatile
Long Term Debt To Capitalization0.03760.03960.2124
Slightly volatile
Total Debt To Capitalization0.04180.0440.2336
Slightly volatile
Debt Equity Ratio0.04370.0460.3769
Slightly volatile
Quick Ratio3.423.60417.1035
Very volatile
Cash Ratio5.82.923912.4464
Very volatile
Days Of Inventory Outstanding111214151
Very volatile
Days Of Sales Outstanding38.4557.997946.8195
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.530.92691.0892
Very volatile
Price To Book Ratio7.465.964311.7428
Slightly volatile
Fixed Asset Turnover7.116.7724.5955
Slightly volatile
Debt Ratio0.03380.03560.1816
Slightly volatile
Price Sales Ratio10.1210.657115.1092
Slightly volatile
Asset Turnover0.250.43290.4782
Very volatile
Gross Profit Margin1.090.87170.9394
Slightly volatile
Price Fair Value7.465.964311.7428
Slightly volatile

Vertex Pharmaceuticals Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap8.4 B16.2 B17.2 B
Very volatile
Enterprise Value8.3 B15.8 B17 B
Very volatile

Vertex Fundamental Market Drivers

Forward Price Earnings24.3309
Cash And Short Term Investments11.2 B

Vertex Upcoming Events

5th of February 2024
Upcoming Quarterly Report
View
6th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
5th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Vertex Pharmaceuticals Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Vertex Pharmaceuticals income statement, its balance sheet, and the statement of cash flows. Vertex Pharmaceuticals investors use historical funamental indicators, such as Vertex Pharmaceuticals's revenue or net income, to determine how well the company is positioned to perform in the future. Although Vertex Pharmaceuticals investors may use each financial statement separately, they are all related. The changes in Vertex Pharmaceuticals's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Vertex Pharmaceuticals's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Vertex Pharmaceuticals Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Vertex Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue170.3 M118.8 M
Total Revenue9.8 B10.3 B
Cost Of Revenue1.3 B1.3 B
Stock Based Compensation To Revenue 0.06  0.06 
Sales General And Administrative To Revenue 0.00  0.00 
Research And Ddevelopement To Revenue 0.38  0.36 
Capex To Revenue(0.03)(0.03)
Revenue Per Share 38.18  40.09 
Ebit Per Revenue 0.38  0.40 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Vertex Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Vertex Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Vertex Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Vertex Pharmaceuticals Stock:
Check out the analysis of Vertex Pharmaceuticals Correlation against competitors.
For more information on how to buy Vertex Stock please use our How to Invest in Vertex Pharmaceuticals guide.
You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.

Complementary Tools for Vertex Stock analysis

When running Vertex Pharmaceuticals' price analysis, check to measure Vertex Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vertex Pharmaceuticals is operating at the current time. Most of Vertex Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Vertex Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vertex Pharmaceuticals' price. Additionally, you may evaluate how the addition of Vertex Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
CEOs Directory
Screen CEOs from public companies around the world
Is Vertex Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vertex Pharmaceuticals. If investors know Vertex will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vertex Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.181
Earnings Share
13.88
Revenue Per Share
38.297
Quarterly Revenue Growth
0.093
Return On Assets
0.1317
The market value of Vertex Pharmaceuticals is measured differently than its book value, which is the value of Vertex that is recorded on the company's balance sheet. Investors also form their own opinion of Vertex Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Vertex Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vertex Pharmaceuticals' market value can be influenced by many factors that don't directly affect Vertex Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Vertex Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Vertex Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vertex Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.